Table 1.
Characteristics of studies reporting clinical characteristics of COVID-19.
| Study | Publication date | Enrolment duration | Maximum follow-up duration (days) | Duration between onset of symptoms and hospitalizati–on (median [range], days) | Study design (RCS/SD/PS) | City | No. of cases | Diagnosis method | Age (median/ mean [range/ IQR], years) | Males (%) | Traveled to or resident of Hubei Province (%) | No. Family -cluster (family) | Current Smokers (%) | Health workers (%) | Underlying diseases |
Severe Cases (%) | Diagnosis of severity | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hyper tension (%) | Diabetes (%) | Cancer (%) | Chronic respiratory /lung diseases (%) | Having any coexisting medical condition (%) | |||||||||||||||||
| Guan et al | Feb-06 | NA | NA | NA | PS | Multi-city* | 1099 | L | 47† (35–58) | 640 (58.2) | 676 (61.5) | NA | 137 (12.4) | 32 (2.9) | 164 (15.0) | 81 (7.4) | 10 (0.9) | 12 (1.1) | 255 (23.2) | 173 (15.7) | ATS |
| Chang et al | Feb-07 | NA | NA | NA | RCS | Beijing | 13 | NA | 34† (34–48) | 10 (77.0) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Zhang et al | Feb- | Jan 18 -Feb 3 | NA | NA | RCS | Beijing | 9 | L | 36 (15–48) | 5 (55.0) | 7 (78.0) | 2 | NA | 1 (11.0) | NA | 1 (11.0) | 0 | NA | NA | NA | NA |
| Yu et al | Feb-17 | Jan 21 | NA | NA | RCS | Beijing | 40 | NA | 40 (21–57) | 26 (65.0) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Zhuang et al | Feb-19 | Jan 1 -Feb 18 | 49 | NA | RCS | Beijing | 26 | L | 39.77† (3–79) | 18 (77.0) | 14 (54.0) | NA | NA | NA | 4 (15.0) | 3 (12.0) | NA | NA | 9 (35.0) | NA | NA |
| Li et al | Feb-10 | Jan 22 -Feb 10 | 20 | NA | RCS | Dazhou | 17 | L | 45 (22–65) | 9 (53.0) | 11 (65.0) | NA | 3 (18.0) | NA | 1 (6.0) | 0 | 0 | 0 | 3 (18.0) | NA | NA |
| Chung et al | Feb-06 | Jan 18 -Jan 27 | NA | NA | RCS | Guangzhou | 21 | L | 51† (29–77) | 13 (62.0) | 18 (86.0) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Zhang et al | Feb-19 | Jan 19 -Feb 5 | 17 | NA | RCS | Nanjing | 42 | L | 43.02† (19–96) | 23 (55.0) | 23 (55.0) | 5 | NA | NA | NA | NA | NA | NA | 5 (12.0) | 0 | NA |
| Wang et al | Jan-30 | Jan 21 -Jan 24 | 14 | 4 (1–11) | RCS | Shanghai | 4 | L | 47.5 (19–63) | 3 (75.0) | 3 (75.0) | NA | NA | NA | NA | 0 | 0 | 0 | 1 (25.0) | 2 (50.0) | NA |
| Song et al | Feb-02 | NA | NA | NA | RCS | Shanghai | 51 | NA | 49 (16–76) | 25 (49.0) | 50 (98.0) | NA | NA | NA | 1 (2.0) | 3 (6.0) | NA | 1 (2.0) | NA | NA | NA |
| Lu et al | Feb-3 | NA | NA | NA | RCS | Shanghai | 50 | L | 50 (NA) | 28 (56.0) | 37 (74.0) | NA | NA | NA | 8 (16.0) | 3 (6.0) | NA | 4 (8.0) | 18 (36.0) | NA | NA |
| Chan et al | Jan-24 | Jan 10 -Jan 15 | 14 | 7 (6–10) | RCS | Shenzhen | 6 | L | 50 (10–66) | 3 (50.0) | 5 (83.3) | 1 | NA | NA | 2 (33.0) | 1 (17.0) | 1 (17.0) | 1 (17.0) | 4 (67.0) | NA | NA |
| Liu et al | Feb-09 | Jan 11 -Jan 20 | 10 | 8.5 (5–16) | RCS | Shenzhen | 12 | L | 63 (10–66) | 8 (67.0) | 11 (91.7) | 2 | NA | NA | 3 (25.0) | 2 (16.7) | 0 | 1 (8.0) | 7 (58.0) | 5 (42.0) | Guidelines |
| Wang et al | Feb-07 | Jan 1 -Jan 28 | 34 | 7 | RCS | Wuhan | 138 | L | 56 (22–92) | 75 (54.3) | 138 (100.0) | NA | NA | 40 (29.0) | 43 (31.2) | 14 (10.1) | 10 (7.2) | 4 (2.9) | 61 (44.2) | 36 (26.1) | ICU |
| Huang et al | Jan-24 | Dec 16 -Jan 2 | 37 | 7 (4–8) | PS | Wuhan | 41 | L | 49 (41–58)‡ | 30 (73.0) | 41 (100.0) | 1 | 3 (7.3) | NA | 6 (14.6) | 8 (19.5) | 1 (2.4) | 1 (2.4) | 13 (31.7) | 13 (31.7) | ICU |
| Liu et al | Jan-24 | Jan 10 -Jan 15 | 15 | 7 (1–20) | RCS | Wuhan | 137 | L | 57 (20–83) | 61 (44.0) | 137 (100.0) | NA | NA | NA | 13 (10.0) | 14 (10.0) | 2 (2.0) | 2 (2.0) | NA | NA | NA |
| Li et al | Feb-09 | NA | NA | NA | SD | Wuhan | 425 | L | 59 (15–89) | 240 (56.0) | 21 (50.0) | NA | NA | 15 (4.0) | NA | NA | NA | NA | NA | NA | NA |
| Chen et al | Jan-29 | Jan 1-Jan 20 | 25 | NA | RCS | Wuhan | 99 | L | 55.5 (21–82) | 67 (68.0) | 49 (49.0) | 1 | NA | NA | 0 | 13 (13.0) | 1 (1.0) | 1 (1.0) | 50 (51.0) | 23 (23.0) | ICU |
| Pan et al | Feb-6 | Dec 30 -Jan 31 | 31 | NA | RCS | Wuhan | 63 | L | 44.9† (NA) | 33 (52.0) | 63 (100.0) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Pan et al | Feb-13 | Jan 12-Feb 6 | 26 | NA | RCS | Wuhan | 21 | L | 40 (25–63) | 6 (29.0) | 21 (100.0) | NA | NA | NA | NA | NA | NA | NA | NA | 0 | NA |
| Chen et al | Feb-4 | Jan 14 -Jan 29 | NA | NA | RCS | Wuhan | 29 | NA | 56 (26–79) | 21 (72.0) | 29 (100.0) | NA | 2 (7.0) | NA | 8 (28.0) | 5 (17.0) | 1 (3.0) | NA | 16 (55.0) | 14 (48.0) | Guidelines |
| Gong et al | Feb-18 | Dec 20 -Jan 22 | NA | NA | RCS | Wuhan | 33 | L | 51 (23–79) | 13 (39.0) | 33 (100.0) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Zhong et al | Feb-13 | NA | NA | NA | RCS | Wuhan | 30 | L | 50 (22–81) | 18 (60.0) | 30 (100.0) | NA | NA | NA | NA | NA | NA | NA | 10 (30.0) | 8 (26.7) | Guidelines |
| Xia et al | Feb-18 | Jan 15 -Feb 8 | NA | (7.44±2.99) | RCS | Wuhan | 52 | L | 54 (23–82) | 24 (46.0) | 52 (100.0) | NA | NA | NA | 25 (48.0) | 26 (50.0) | NA | NA | NA | 12 (23.0) | Guidelines |
| Yang et al | Feb-21 | Dec 24 -Jan 26 | NA | NA | RCS | Wuhan | 52 | L | 59 (13.3) | 35 (67.0) | 52 (100.0) | NA | 2 (4.0) | NA | NA | 9 (17.0) | 2 (4.0) | 2 (4.0) | 21 (40.0) | 52 (100.0) | ICU |
| Du et al | Feb-9 | Jan 27 -Feb 1 | NA | NA | RCS | Xian | 7 | NA | 40 (24–55) | 4 (57.0) | 2 (28.5) | 3 | 0 | 0 | NA | NA | NA | NA | NA | NA | NA |
| Gao et al | Feb-6 | NA | NA | NA | RCS | Xian | 10 | L | 41.8† (22–70) | 6 (60.0) | 9 (90.0) | NA | NA | NA | NA | NA | NA | NA | NA | 0 | NA |
| Liu et al | Feb-18 | NA | NA | NA | RCS | Xiaogan | 41 | L | 48 (19–64) | 32 (78.0) | 28 (68.0) | NA | NA | NA | 5 (12.0) | 2 (5.0) | NA | NA | NA | 5 (12.0) | NA |
| Xu et al | Feb-20 | Jan 10 -Jan 26 | NA | 2 (1–4) | RCS | Zhejiang | 62 | L | 41† (32–52) | 32 (58.0) | 62 (100.0) | NA | NA | NA | 5 (8.0) | 1 (2.0) | NA | 1 (2.0) | 20 (32.0) | 1 (2.0) | Guidelines |
| Yu et al | Feb-03 | Jan 21 -Feb 2 | NA | 5.5 (3–13) | RCS | Beijing | 25 | L | 37.9† (3–79) | 16 (64.0) | 23 (92.0) | 3 | NA | NA | 1 (4.0) | 3 (12.0) | NA | NA | NA | NA | NA |
| Huang et al | Feb-16 | Jan 23 -Feb 24 | NA | NA | RCS | Guangzhou | 35 | L | 44 (12–74) | 19 (54.0) | 20 (57.0) | NA | 5 (14.0) | NA | 1 (3.0) | 2 (6.0) | NA | 1 (3.0) | NA | NA | NA |
| Wang et al | Feb-15 | Jan 19 -Feb 3 | NA | NA | RCS | Zhejiang | 52 | L | 44 (13–73) | 29 (56.0) | 16 (30.0) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Fang et al | Feb-25 | Jan 22 -Feb 18 | NA | NA | RCS | Hefei | 79 | L | 45.1† (5–91) | 18 (75.0) | NA | NA | NA | NA | 11 (46.0) | NA | NA | NA | NA | 24 (30.0) | Guidelines |
| Chen et al | Feb-19 | Jan 24 -Feb 8 | NA | 7 (4–9.5) | RCS | Wuhan | 54 | L | 58.5 (43–69) | 27 (50.0) | NA | NA | NA | NA | 13 (24.0) | NA | NA | NA | NA | 31 (57.0) | Guidelines |
| Xian et al | Feb-17 | Jan 21 -Jan 27 | NA | NA | RCS | Nanchang | 49 | L | 42.0† (18–78) | 33 (67.0) | 46 (94.0) | NA | 3 (6.0) | NA | 6 (12.0) | 2 (4.0) | NA | NA | NA | 9 (18.0) | Guidelines |
| Cao et al | Feb-28 | Jan 1 -Feb 15 | NA | NA | RCS | Wuhan | 36 | L | 72.5† (61–82) | 19 (55.5) | NA | NA | NA | NA | 17 (47.2) | 8 (22.2) | NA | 0.583 | NA | NA | NA |
| Li et al | Feb-24 | Jan 26 -Feb 6 | NA | NA | RCS | Anhui | 12 | L | 37 (21–71) | 8 (66.7) | 12 (100.0) | NA | 0.333 | NA | 2 (16.7) | NA | NA | NA | NA | 0 | NA |
| Sun et al | Feb-24 | Jan 21 -Feb 8 | NA | NA | RCS | Tianjin | 88 | L | 48.5† (9–91) | 49 (55.7) | 26 (29.5) | NA | NA | NA | 22 (25.0) | 10 (11.4) | NA | NA | NA | 32 (36.4) | Guidelines |
| Ji et al | Feb-24 | Jan 19 -Feb 1 | NA | NA | RCS | Jingzhou | 45 | L | 45.4† (21–67) | 27 (60.0) | 37 (82.2) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Wang et al | Feb-24 | Jan 1 -Feb 14 | NA | NA | RCS | Wuhan | 159 | L | 45.5† (20–84) | 66 (41.5) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Yu et al | Feb-26 | Jan 17 -Jan 28 | NA | NA | RCS | Wenzhou | 40 | L | 45.9† (23–67) | 22 (55.0) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| XIAO et al | Feb-27 | Jan 23 -Feb 8 | NA | NA | RCS | Chongqing | 143 | L | 45.1† | 73 (51.0) | 76 (53.0) | NA | NA | NA | 17 (12.0) | 10 (7.0) | NA | 4 (3.0) | NA | 36 (25.0) | Guidelines |
| Wu et al | Feb-28 | Jan 22 -Feb 14 | NA | NA | RCS | Jiangsu | 80 | L | 46.1† | 39 (49.0) | 80 (100.0) | 5 | NA | NA | 25 (31.0) | 5 (6.0) | 1 (1.0) | 1 (1.0) | NA | 3 (4.0) | Guidelines |
| Xu et al | Feb-19 | Jan 23 -Feb 4 | NA | NA | RCS | Guangzhou | 90 | L | 50 (18–86) | 39 (43.0) | 86 (96.0) | NA | NA | NA | 17 (19.0) | 5 (6.0) | 2 (2.0) | 1 (1.0) | 45 (50.0) | NA | Guidelines |
NA = Not available. RCS = Retrospective case series. SD = Surveillance data. PS = Prospective study. L = Laboratory-confirmed. Guideline = Guidelines of 2019-nCoV infection from the National Health Commission of the People's Republic of China. ICU = Being admitted to ICU. ATS = American Thoracic Society guideline on admission. All studies were published in 2020. December belongs to 2019. If there is no mark, the median and range were used to represent age. *All cases originated from 31 provinces, municipalities and autonomous regions other than Hubei province. †These values are average values. ‡These data are interquartile range.